|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 4,459,310, assigned to Roche, covers a class of pharmaceutical compounds with specific chemical structures used primarily as nonsteroidal anti-inflammatory drugs (NSAIDs). The patent's claims focus on the compounds' chemical makeup, with scope extending to pharmaceutical compositions and methods of use. It played a significant role in Roche's NSAID portfolio and has influenced subsequent patent filings around structural analogs. The patent expires in 2004, with its expiration opening the patent landscape to generic competition.
Scope of Patent 4,459,310
Chemical Composition and Structural Scope
The patent claims a class of indole derivatives characterized by substitution at specific positions on the indole ring and attached with particular functional groups that confer anti-inflammatory activity. The core of the patent covers compounds where:
- The indole ring (a fused benzene and pyrrole system) is substituted at positions 1, 2, or 3.
- The substituents include various alkyl, acyl, or other functional groups.
- The compounds are prepared with specific stereochemistry, which is detailed in dependent claims.
Claims Breakdown
-
Compound Claims: Cover specific compounds with defined chemical structures, including the core indole nucleus with certain substituents.
-
Process Claims: Describe methods for synthesizing the compounds, involving steps like chlorination, alkylation, or acylation.
-
Use Claims: Cover the use of the compounds for treating inflammation, pain, or other related conditions, emphasizing therapeutic applications.
Limitations
- Restricted to compounds with the particular substitution patterns specified.
- Does not claim all indole derivatives outside these substitution patterns.
- The scope is confined to compounds with anti-inflammatory activity, excluding other potential therapeutic uses.
Patent Landscape
Patent Family and Related Patents
- Roche filed related patents around the same chemical class, including composition of matter patents and process patents.
- Subsequent filings included method-of-use patents for treating specific inflammatory conditions.
- Several patents have cited or are cited by 4,459,310 as prior art.
Competitive Patents
- Other pharmaceutical companies filed patents on structurally similar NSAID compounds, including those with different heterocyclic cores.
- Generic manufacturers have challenged or designed around these compounds after patent expiration.
Patent Expiry and Market Impact
- The patent expired in 2004, allowing generic manufacturers to produce indole-based NSAIDs or structurally similar compounds.
- The expiration facilitated increased generic competition, reducing the drug's market exclusivity and price.
Key Structural Features and Innovation
- The patent's innovation centered on a specific subclass of indole derivatives with anti-inflammatory properties.
- The claims specify precise substitution patterns critical for activity, narrowing the scope but offering strong protection for the covered compounds.
- The patent contributed to Roche's early 1990s NSAID portfolio, including drugs like etodolac derivatives.
Notable Legal and Commercial Impacts
- The patent's scope limited generic entry prior to its expiration.
- It shaped subsequent patent strategies by competitors seeking to design around the claims, often modifying substituents to avoid infringement.
- Post-expiration, many companies launched generic indole NSAIDs, eroding Roche's market share.
Critical Analysis
- The patent's narrow scope, while detailed, allowed for the development of similar compounds outside its claims.
- The detailed chemical claims provided a robust barrier during patent life but were vulnerable to around-the-claims innovations after expiry.
- Patent portfolio strategies around this compound included process and use patents to extend market exclusivity and defend against generic challenges.
Key Takeaways
- U.S. Patent 4,459,310 claims a specific class of indole NSAIDs with defined structural features.
- The patent's claims cover certain compounds, their synthesis, and therapeutic uses, but exclude broader classes of compounds.
- Its expiration in 2004 enabled generic competitors to enter the market, reducing Roche’s market share.
- The landscape includes related patents on similar structures, process innovations, and therapeutic methods.
- The patent exemplifies detailed chemical claim drafting aimed at protecting a narrow but valuable drug class.
FAQs
1. How broad are the claims of U.S. Patent 4,459,310?
The claims are narrow, covering specific indole derivatives with defined substitutions. They do not extend to all indole NSAIDs or other heterocyclic compounds.
2. Did the patent prevent other companies from developing similar NSAIDs?
Initially, yes, during its active term until 2004. Post-expiration, competitors developed and marketed structurally similar drugs outside its claims.
3. What was the primary innovation claimed in this patent?
The specific chemical structure of indole derivatives with anti-inflammatory activity, including certain substitution patterns, was the key innovation.
4. Are there any process or use claims associated with this patent?
Yes, claims include methods for synthesizing the compounds and methods of using them for treating inflammation and pain.
5. How did the patent landscape evolve post-expiration?
Generic competition increased after 2004, with new patents filed for alternative compounds or formulations, but the original scope of 4,459,310 was no longer enforceable.
References
- U.S. Patent 4,459,310
- [1] Patent citations and related applications (specific patent databases, e.g., USPTO or EPO).
More… ↓
⤷ Start Trial
|
